- AudioEye’s Return on Invested Capital (ROIC) is -14.04%, significantly lower than its Weighted Average Cost of Capital (WACC) of 7.73%, indicating inefficiency in generating returns to cover its cost of capital.
- Brightcove Inc. has the least negative ROIC to WACC ratio among peers, suggesting it is relatively closer to covering its cost of capital.
- ClearPoint Neuro, Inc. and Rekor Systems, Inc. face significant challenges with their ROIC to WACC ratios, indicating substantial gaps between the returns generated and the cost of capital.
AudioEye, Inc. (NASDAQ:AEYE) is a company that focuses on digital accessibility solutions, helping businesses make their digital content accessible to individuals with disabilities. The company operates in a competitive landscape with peers like Brightcove Inc., ClearPoint Neuro, Inc., Rekor Systems, Inc., DarioHealth Corp., and Apyx Medical Corporation. These companies, while operating in different sectors, share the common challenge of managing their capital efficiently.
AudioEye’s Return on Invested Capital (ROIC) is -14.04%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 7.73%. This negative ROIC indicates that AudioEye is not generating enough returns to cover its cost of capital, which is a critical measure of financial health. The ROIC to WACC ratio of -1.82 further highlights this inefficiency in capital utilization.
When comparing AudioEye to its peers, Brightcove Inc. emerges as the company with the least negative ROIC to WACC ratio at -1.56. Despite its negative ROIC of -11.66%, Brightcove’s WACC is 7.48%, suggesting it is relatively closer to covering its cost of capital compared to others. This positions Brightcove as a relatively better performer in terms of capital efficiency.
ClearPoint Neuro, Inc. and Rekor Systems, Inc. show more significant challenges with ROICs of -40.55% and -107.12%, respectively. Their ROIC to WACC ratios of -5.20 and -8.14 indicate a substantial gap between the returns generated and the cost of capital. This suggests that these companies face more significant hurdles in achieving capital efficiency.
DarioHealth Corp. and Apyx Medical Corporation also struggle with negative ROICs of -18.93% and -26.00%, respectively. Their ROIC to WACC ratios of -2.82 and -2.27 reflect ongoing challenges in generating returns that exceed their cost of capital. These figures underscore the broader issue of capital inefficiency across the peer group, with Brightcove Inc. standing out as the relatively better performer.
